CDK19 and neoplasm: By contrast, CDK8/CDK19 enhance AR activity and suppress MYC expression; therefore, inhibition of these kinases leads to dampening of AR signalling concomitant with MYC upregulation, resulting in aberrant G1/S transition, activation of a DNA damage response and significant anti-tumour activity in CRPC xenografts [137].